Valuation: Telix Pharmaceuticals Limited

Market Cap 5.32B 3.68B 3.23B 2.98B 2.79B 5.23B 347B 35.75B 13.85B 171B 13.83B 13.52B 595B P/E 2026 *
996x
P/E 2027 * 111x
Enterprise Value 5.73B 3.96B 3.48B 3.21B 3B 5.62B 374B 38.48B 14.9B 184B 14.88B 14.55B 640B EV / Sales 2026 *
4.22x
EV / Sales 2027 * 3.63x
Free-Float
83.23%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Telix Pharmaceuticals Limited

1 day-0.32%
1 week+10.81%
Current month+20.34%
1 month+17.72%
3 months+25.44%
6 months+31.88%
Current year+40.00%
1 week 14.07
Extreme 14.07
16.06
1 month 12.17
Extreme 12.17
16.06
Current year 8.26
Extreme 8.26
16.06
1 year 8.26
Extreme 8.26
25.87
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 2017-01-02
Director of Finance/CFO 60 2022-07-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 2017-01-02
Chairman 66 2026-02-02
Director/Board Member 68 2018-06-18
Date Insider Type Main position Quantity % Market Cap.
06-10Buy

Director

10,200 0.0030%
05-25Free

Director

30,048 0.0089%
05-25Free

Director

23,139 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%+10.81%-35.71%+33.11% 3.68B
+1.67%+9.28%-5.05%+2.95% 45.45B
+4.84%+9.48%+364.58%+617.51% 36.09B
+1.02%+3.92%+5.09%+55.89% 30.81B
+1.13%+11.37%+17.73%-12.61% 30.98B
+0.23%-0.86%+12.75%+21.10% 24.62B
+8.79%+12.16% - - 14.78B
+3.28%+15.25%+70.47%+135.61% 14.65B
+1.88%+8.59%+13.76%+21.62% 13.3B
+2.07%+5.50%+95.50%+100.00% 12.65B
Average +2.50%+6.71%+59.90%+108.35% 22.7B
Weighted average by Cap. +2.50%+6.50%+76.53%+131.62%

Financials

2026 *2027 *
Net sales 1.36B 939M 825M 760M 710M 1.33B 88.59B 9.12B 3.53B 43.67B 3.53B 3.45B 152B 1.59B 1.1B 966M 890M 832M 1.56B 104B 10.68B 4.14B 51.15B 4.13B 4.04B 178B
Net income 6.1M 4.22M 3.71M 3.41M 3.19M 5.99M 398M 40.96M 15.86M 196M 15.84M 15.49M 682M 43.61M 30.17M 26.5M 24.42M 22.83M 42.82M 2.85B 293M 113M 1.4B 113M 111M 4.88B
Net Debt 405M 280M 246M 227M 212M 398M 26.46B 2.72B 1.05B 13.04B 1.05B 1.03B 45.33B 443M 307M 269M 248M 232M 435M 28.95B 2.98B 1.15B 14.27B 1.15B 1.13B 49.59B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
26-06-25 A$15.68 -0.32% 1,745,963
26-06-24 A$15.73 +8.04% 3,701,343
26-06-23 A$14.56 +2.46% 1,878,642
26-06-22 A$14.21 -2.00% 1,273,119
26-06-19 A$14.50 +1.26% 3,759,644
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
15.68AUD
Average target price
23.32AUD
Spread / Average Target
+48.74%

Quarterly revenue - Rate of surprise